{"id":"https://openalex.org/W4282912962","doi":"https://doi.org/10.1158/1538-7445.am2022-ct252","title":"Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors","display_name":"Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282912962","doi":"https://doi.org/10.1158/1538-7445.am2022-ct252"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-ct252","doi":"https://doi.org/10.1158/1538-7445.am2022-ct252","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-ct252","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030169825","display_name":"Diwakar Davar","orcid":"https://orcid.org/0000-0002-7846-8055","observed_orcids":["https://orcid.org/0000-0002-7846-8055"]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diwakar Davar","raw_affiliation_strings":["1University of Pittsburgh Medical Center, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Pittsburgh Medical Center, Pittsburgh, PA;","institution_ids":["https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040489877","display_name":"Stina Mui Singel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stina M. Singel","raw_affiliation_strings":["2Ascendis Pharma, Palo Alto, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Ascendis Pharma, Palo Alto, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086027996","display_name":"Gil Nyamuswa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gil Nyamuswa","raw_affiliation_strings":["2Ascendis Pharma, Palo Alto, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Ascendis Pharma, Palo Alto, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114036851","display_name":"Tuan\u2010Anh Tran","orcid":"https://orcid.org/0000-0003-3580-6189","observed_orcids":["https://orcid.org/0000-0003-3580-6189"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tuan-Anh Tran","raw_affiliation_strings":["2Ascendis Pharma, Palo Alto, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Ascendis Pharma, Palo Alto, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100753551","display_name":"Yang\u2010Chang Wu","orcid":"https://orcid.org/0000-0001-7815-2686","observed_orcids":["https://orcid.org/0000-0001-7815-2686"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yang Wu","raw_affiliation_strings":["2Ascendis Pharma, Palo Alto, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Ascendis Pharma, Palo Alto, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076779423","display_name":"Jaspreet Singh Grewal","orcid":"https://orcid.org/0000-0002-2219-7655","observed_orcids":["https://orcid.org/0000-0002-2219-7655"]},"institutions":[{"id":"https://openalex.org/I202709704","display_name":"Norton Healthcare","ror":"https://ror.org/0266h1q26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I202709704"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaspreet Grewal","raw_affiliation_strings":["3Norton Cancer Institute, Louisville, KY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Norton Cancer Institute, Louisville, KY;","institution_ids":["https://openalex.org/I202709704"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034486818","display_name":"Morteza Aghmesheh","orcid":"https://orcid.org/0000-0003-1664-4743","observed_orcids":["https://orcid.org/0000-0003-1664-4743"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Morteza Aghmesheh","raw_affiliation_strings":["4Southern Medical Day Care Centre, Wollongong, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Southern Medical Day Care Centre, Wollongong, Australia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044613951","display_name":"Alexander I. Spira","orcid":"https://orcid.org/0000-0003-1303-0447","observed_orcids":["https://orcid.org/0000-0003-1303-0447"]},"institutions":[{"id":"https://openalex.org/I4210122908","display_name":"Virginia Cancer Specialists","ror":"https://ror.org/03tbabt10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210122908"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander Spira","raw_affiliation_strings":["5Virginia Cancer Specialists, Fairfax, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Virginia Cancer Specialists, Fairfax, VA;","institution_ids":["https://openalex.org/I4210122908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018587056","display_name":"Vinod Ganju","orcid":"https://orcid.org/0000-0003-4713-7752","observed_orcids":["https://orcid.org/0000-0003-4713-7752"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vinod Ganju","raw_affiliation_strings":["6Peninsula and Southeast Oncology, Franskton, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Peninsula and Southeast Oncology, Franskton, Australia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052270503","display_name":"Jamie Green Rand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jamie Rand","raw_affiliation_strings":["7City of Hope, Duarte, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7City of Hope, Duarte, CA;","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049181098","display_name":"Sophia Frentzas","orcid":"https://orcid.org/0000-0002-6917-9737","observed_orcids":["https://orcid.org/0000-0002-6917-9737"]},"institutions":[{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Sophia Frentzas","raw_affiliation_strings":["8Monash Health, Clayton, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Monash Health, Clayton, Australia;","institution_ids":["https://openalex.org/I4210121067"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051445471","display_name":"David J. Bajor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108791","display_name":"University Hospitals Cleveland Medical Center","ror":"https://ror.org/01gc0wp38","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799343972","https://openalex.org/I4210108791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Bajor","raw_affiliation_strings":["9University Hospitals Cleveland Medical Center, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9University Hospitals Cleveland Medical Center, Cleveland, OH;","institution_ids":["https://openalex.org/I4210108791"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111512954","display_name":"Nashat Y. Gabrail","orcid":"https://orcid.org/0009-0007-3885-3622","observed_orcids":["https://orcid.org/0009-0007-3885-3622"]},"institutions":[{"id":"https://openalex.org/I4210100169","display_name":"Gabrail Cancer Center","ror":"https://ror.org/015hpqr35","country_code":"US","type":"other","lineage":["https://openalex.org/I4210100169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nashat Gabrail","raw_affiliation_strings":["10Gabrail Cancer Center, Canton, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Gabrail Cancer Center, Canton, OH","institution_ids":["https://openalex.org/I4210100169"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"CT252","last_page":"CT252"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.6377000212669373,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.6377000212669373,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.35740000009536743,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10371","display_name":"Immune Response and Inflammation","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/resiquimod","display_name":"resiquimod","score":0.9779999852180481},{"id":"https://openalex.org/keywords/tlr7-8-agonist","display_name":"TLR7/8 agonist","score":0.9660000205039978},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5680000185966492},{"id":"https://openalex.org/keywords/intratumoral-injection","display_name":"intratumoral injection","score":0.7289999723434448},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.5099999904632568},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.5590000152587891},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.6430000066757202},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5189999938011169},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7540000081062317},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7950000166893005},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.5180000066757202}],"concepts":[{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7978836894035339},{"id":"https://openalex.org/C2779836521","wikidata":"https://www.wikidata.org/wiki/Q14914081","display_name":"TLR7","level":5,"score":0.6266332864761353},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.5987672805786133},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.49054640531539917},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4426059126853943},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.43272674083709717},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.43178704380989075},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42889389395713806},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4119173586368561},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.40544208884239197},{"id":"https://openalex.org/C136449434","wikidata":"https://www.wikidata.org/wiki/Q428253","display_name":"Innate immune system","level":3,"score":0.3970752954483032},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3512008786201477},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.313901424407959},{"id":"https://openalex.org/C2776709828","wikidata":"https://www.wikidata.org/wiki/Q408004","display_name":"Toll-like receptor","level":4,"score":0.29007840156555176},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.281917929649353},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.24948671460151672}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-ct252","doi":"https://doi.org/10.1158/1538-7445.am2022-ct252","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-ct252","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4308398788","https://openalex.org/W4388080833","https://openalex.org/W4296368840","https://openalex.org/W3212139125","https://openalex.org/W3212702768","https://openalex.org/W6902201004","https://openalex.org/W6958250708","https://openalex.org/W6902062226","https://openalex.org/W2499211377","https://openalex.org/W6902193285"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Toll-like":[2],"receptors":[3],"(TLRs)":[4],"play":[5],"a":[6,42,51,101,107,137,182,264,355],"key":[7],"role":[8],"in":[9,30,147,165,188,191,251,284,322,446,450],"innate":[10,18,160],"immune":[11,21,28,163],"cell":[12,128,338],"recognition":[13,67],"of":[14,33,49,65,77,174,245,271,314,378,440,462],"foreign":[15],"pathogens,":[16],"stimulating":[17],"and":[19,79,89,106,119,146,161,169,220,239,257,335,359,371,386,396,436],"adaptive":[20,162],"responses.":[22],"TLR":[23],"agonists":[24],"amplify":[25],"tumor":[26,167],"antigen-specific":[27],"responses":[29,83],"the":[31,59,112,124,166,172,231,235,319,463],"context":[32],"anti-PD-1":[34],"therapy.":[35],"TransCon":[36,55,93,142,153,246,272,315,367,441],"TLR7/8":[37,53,56,94,143,154,247,273,316,368,442],"Agonist":[38,57,95,144,155,248,274,317,369,443],"is":[39,156,181,397],"designed":[40],"as":[41,218],"long-acting":[43],"prodrug":[44],"to":[45,61,111,121,140,158,229,381],"provide":[46],"localized":[47],"delivery":[48],"resiquimod,":[50,100],"potent":[52,81],"agonist.":[54],"has":[58],"potential":[60],"improve":[62],"on":[63,116,123,133],"challenges":[64],"pattern":[66],"receptor":[68],"agonist":[69],"treatments":[70],"by":[71,212,383],"providing":[72,136],"prolonged":[73],"high":[74],"local":[75],"concentrations":[76],"resiquimod":[78,122],"promoting":[80],"anti-tumoral":[82],"while":[84],"reducing":[85],"systemic":[86],"drug":[87],"exposure":[88],"related":[90],"adverse":[91],"events.":[92],"comprises":[96],"3":[97,189,303],"main":[98],"components:":[99],"polymeric":[102],"hydrogel":[103,113],"microparticle":[104,114],"carrier,":[105],"linker":[108],"bound":[109],"permanently":[110],"carrier":[115],"one":[117],"end":[118],"transiently":[120],"other.":[125],"TLR-mediated":[126],"T":[127,134],"activation":[129],"induces":[130],"PD-1":[131],"expression":[132],"cells,":[135],"clear":[138],"rationale":[139],"study":[141,187,439],"alone":[145,249,275,444],"combination":[148,252,447],"with":[149,194,253,268,279,326,448,452],"pembrolizumab":[150,449],"(pembro).":[151],"Intratumoral":[152],"expected":[157],"stimulate":[159],"response":[164,382],"microenvironment":[168],"further":[170],"enhance":[171],"activity":[173,293,374],"checkpoint":[175],"inhibitors":[176],"like":[177],"pembro.":[178,254,327],"Methods:":[179],"transcendIT-101":[180],"multicenter,":[183],"first-in-human,":[184],"Phase":[185,241],"1/2":[186],"parts":[190],"adult":[192],"patients":[193,204,451],"locally":[195,453],"advanced,":[196],"unresectable,":[197],"recurrent,":[198],"or":[199,250,278,445,455],"metastatic":[200,456],"solid":[201,285,457],"tumors.":[202],"All":[203],"must":[205],"have":[206,291],"at":[207,318],"least":[208],"2":[209,242,258,324],"measurable":[210],"lesions":[211],"RECIST":[213,384],"1.1":[214,385],"that":[215],"are":[216,228,332,366],"predesignated":[217],"target-injected":[219],"target":[221],"non-injected":[222],"lesions,":[223],"respectively.":[224],"The":[225],"primary":[226],"objectives":[227,365],"evaluate":[230,310],"safety,":[232],"tolerability,":[233],"define":[234],"maximum":[236],"tolerated":[237],"dose":[238,243,434,437],"recommended":[240],"(RP2D)":[244],"Parts":[255],"1":[256],"Dose":[259,305],"Escalation":[260],"(Phase":[261,307],"1)":[262,277,333],"use":[263],"standard":[265],"3+3":[266],"design":[267,358],"increasing":[269],"doses":[270],"(Part":[276,294],"200":[280],"mg":[281],"intravenous":[282],"pembro":[283,288],"tumors":[286,343,458],"where":[287],"monotherapy":[289],"may":[290],"clinical":[292,312],"2).":[295],"Each":[296,349],"part":[297],"will":[298,309,351,360],"enroll":[299,361],"\u224820":[300],"patients.":[301,363],"Part":[302,323],"Combination":[304],"Expansion":[306],"2)":[308,340],"preliminary":[311],"efficacy":[313],"RP2D":[320],"determined":[321],"combined":[325],"Currently":[328],"planned":[329],"expansion":[330,438],"cohorts":[331],"head":[334],"neck":[336],"squamous":[337],"carcinoma,":[339],"other":[341],"HPV-associated":[342],"(anal,":[344],"vulvar,":[345],"cervical,":[346],"penile,":[347],"vaginal).":[348],"cohort":[350],"be":[352],"analyzed":[353],"using":[354,375],"Simon":[356],"2-stage":[357],"\u224850":[362],"Secondary":[364],"pharmacokinetics":[370],"its":[372],"antitumor":[373],"ORR,":[376],"duration":[377],"response,":[379],"time":[380],"itRECIST;":[387],"progression-free":[388],"survival;":[389],"overall":[390],"survival.":[391],"Recruitment":[392],"started":[393],"March":[394],"2021":[395],"ongoing":[398],"(NCT04799054).":[399],"Citation":[400],"Format:":[401],"Diwakar":[402],"Davar,":[403],"Stina":[404],"M.":[405],"Singel,":[406],"Gil":[407],"Nyamuswa,":[408],"Tuan-Anh":[409],"Tran,":[410],"Yang":[411],"Wu,":[412],"Jaspreet":[413],"Grewal,":[414],"Morteza":[415],"Aghmesheh,":[416],"Alexander":[417],"Spira,":[418],"Vinod":[419],"Ganju,":[420],"Jamie":[421],"Rand,":[422],"Sophia":[423],"Frentzas,":[424],"David":[425],"Bajor,":[426],"Nashat":[427],"Gabrail.":[428],"transcendIT-101:":[429],"A":[430],"phase":[431],"1/2,":[432],"open-label,":[433],"escalation":[435],"advanced":[454],"[abstract].":[459],"In:":[460],"Proceedings":[461],"American":[464],"Association":[465],"for":[466],"Cancer":[467,478],"Research":[468],"Annual":[469],"Meeting":[470],"2022;":[471],"2022":[472],"Apr":[473],"8-13.":[474],"Philadelphia":[475],"(PA):":[476],"AACR;":[477],"Res":[479],"2022;82(12_Suppl):Abstract":[480],"nr":[481],"CT252.":[482]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2022-06-16T00:00:00"}